539 results on '"Westerhout, Cynthia M."'
Search Results
52. Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial
53. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
54. Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes
55. Participation in a Heart Failure Clinical Trial
56. Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis
57. Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged
58. Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial
59. Baseline Q-Wave Surpasses Time From Symptom Onset as a Prognostic Marker in ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention
60. Time from first medical contact to reperfusion in ST elevation myocardial infarction: A Which Early ST Elevation Myocardial Infarction Therapy (WEST) substudy
61. Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial
62. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.
63. Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: Insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial
64. Association of global weather changes with acute coronary syndromes: gaining insights from clinical trials data
65. Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase
66. Integrating ancillary studies in a large clinical trial: The design and rationale of the APEX library
67. Sex differences in patients seeking medical attention for prodromal symptoms before an acute coronary event
68. Guideline adjudicated fibrinolytic failure: Incidence, findings, and management in a contemporary clinical trial
69. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial
70. Computing the polytomous discrimination index
71. Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex
72. No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: Insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial
73. Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial
74. Estimating the Empirical Estimate and Variance of Survival Using a Weighted Composite Endpoint Approach
75. Routine invasive management early after fibrinolysis: Relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials
76. Influence of Clinical Trials of Acute Coronary Syndrome Beyond the Primary Hypothesis
77. Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: Insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial
78. The forgotten lead: Does aVR ST-deviation add insight into the outcomes of ST-elevation myocardial infarction patients?
79. Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint
80. Aborted myocardial infarction after primary percutaneous coronary intervention: Magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
81. Short- and Long-Term Risk Stratification in Acute Coronary Syndromes: The Added Value of Quantitative ST-Segment Depression and Multiple Biomarkers
82. Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial
83. Mode of hospital presentation in patients with non-ST-elevation myocardial infarction: Implications for strategic management
84. Non-participation in a Heart Failure Clinical Trial: Perspectives and Opportunities from the VICTORIA Trial and Simultaneous Registry
85. Novel Biomarkers, ST‐Elevation Resolution, and Clinical Outcomes Following Primary Percutaneous Coronary Intervention
86. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial
87. High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction
88. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS
89. Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non–ST-segment elevation acute coronary syndromes
90. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease
91. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial
92. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial
93. Resolution of ST-segment depression: a new prognostic marker in ST-segment elevation myocardial infarction
94. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.
95. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study
96. Differences in admission rates and outcomes between men and women presenting to emergency departments with coronary syndromes
97. The authors’ reply
98. A Novel Enoxaparin Regime for St Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: a West Sub-Study
99. Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women
100. Primary Percutaneous Coronary Intervention Compared With Fibrinolysis for Myocardial Infarction in Diabetes Mellitus: Results From the Primary Coronary Angioplasty vs Thrombolysis–2 Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.